Phenyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9682059-B2
Publication Date
2017-06-20
Expiration Date
Abstract
The present invention provides a pharmaceutical composition for preventing and/or treating a epilepsy or epilepsy-related syndrome, for example an intractable epilepsy or its related syndrome such as drug-resistant epilepsy, comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating epilepsy or epilepsy-related syndrome.
Core Innovation
The invention relates to a method of treating intractable epilepsy or an epilepsy-related syndrome in a subject by administering a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof. Formula 1 includes X as a halogen, n as an integer from 1 to 5, R1 as a linear or branched alkyl group of C1-C4, and A and B as hydrogen or a carbamoyl group, with A and B not being carbamoyl derivatives at the same time.
R2 and R3 are selected from hydrogen, linear or branched alkyl groups of C1-C4, a cycloalkyl group of C3-C8, and a benzyl group. The compound class is further described with stereochemical forms including racemate, enantiomer, diastereomer, and mixtures of enantiomers or diastereomers.
The dependent claims and examples identify particular carbamate compounds with halogenated phenyl groups, including 2-chlorophenyl, 2,4-dichlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2-fluorophenyl, and 2-iodophenyl variants, together with named stereochemical forms such as (S), (R), (S,S), and (R,R). The treated conditions include intractable localization-related epilepsy, intractable secondary generalized seizure, intractable complex partial seizure, and intractable status epilepticus.
Claims Coverage
The document includes one independent claim directed to treating intractable epilepsy or an epilepsy-related syndrome by administering a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof. The inventive features are concentrated in the formula 1 compound definition, stereochemical presentation, and the narrowing of treated seizure subtypes.
Treating intractable epilepsy with formula 1 compound administration
A method of treating intractable epilepsy or an epilepsy-related syndrome in a subject by administering to the subject a therapeutically effective amount of a compound of formula 1 or a pharmaceutically acceptable salt thereof.
Formula 1 halogen and alkyl framework
In formula 1, X is a halogen, n is an integer from 1 to 5, and R1 is a linear or branched alkyl group of C1-C4.
Mutually exclusive carbamoyl placement on A and B
In formula 1, A is hydrogen or a carbamoyl group and B is hydrogen or a carbamoyl group, with A and B not being carbamoyl derivatives at the same time.
R2 and R3 selection
In formula 1, R2 and R3 are selected from hydrogen, a linear or branched alkyl group of C1-C4, a cycloalkyl group of C3-C8, and benzyl group.
Stereochemical presentation of phenyl carbamate compound
The phenyl carbamate compound is present as a racemate, an enantiomer, a diastereomer, or mixtures of enantiomers or diastereomers.
Specific intractable seizure subtype treatment
The treatment is directed to intractable localization-related epilepsy, intractable secondary generalized seizure, intractable complex partial seizure, or intractable status epilepticus.
Claim coverage centers on administering a therapeutically effective amount of a formula 1 compound or pharmaceutically acceptable salt for intractable epilepsy or an epilepsy-related syndrome, with structural limits on X, n, R1, A, B, R2, and R3, plus stereochemical and seizure-subtype refinements.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?